Regeneron Pharmaceuticals (NASDAQ:REGN) Rating Reiterated by Cantor Fitzgerald

Cantor Fitzgerald reiterated their neutral rating on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) in a research report sent to investors on Monday morning, Benzinga reports. Cantor Fitzgerald currently has a $925.00 price target on the biopharmaceutical company’s stock.

Other equities research analysts also recently issued research reports about the company. StockNews.com raised Regeneron Pharmaceuticals from a buy rating to a strong-buy rating in a research report on Friday, April 12th. Morgan Stanley lifted their price objective on Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the company an overweight rating in a research report on Wednesday, March 13th. Royal Bank of Canada reaffirmed an outperform rating and issued a $1,189.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Tuesday, April 9th. Sanford C. Bernstein began coverage on Regeneron Pharmaceuticals in a research report on Tuesday, March 12th. They issued an outperform rating and a $1,125.00 price objective for the company. Finally, Barclays lifted their price objective on Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the company an overweight rating in a research report on Tuesday, January 23rd. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Regeneron Pharmaceuticals has a consensus rating of Moderate Buy and an average target price of $976.41.

Regeneron Pharmaceuticals Stock Down 0.8 %

Regeneron Pharmaceuticals stock opened at $893.99 on Monday. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.69 and a quick ratio of 4.94. Regeneron Pharmaceuticals has a 1-year low of $684.80 and a 1-year high of $998.33. The company has a market cap of $98.12 billion, a PE ratio of 25.73, a price-to-earnings-growth ratio of 2.58 and a beta of 0.11. The stock’s 50 day moving average price is $954.14 and its 200 day moving average price is $890.55.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $10.73 by $1.13. The firm had revenue of $3.43 billion during the quarter, compared to analysts’ expectations of $3.29 billion. Regeneron Pharmaceuticals had a return on equity of 17.61% and a net margin of 30.14%. Regeneron Pharmaceuticals’s revenue was up .6% on a year-over-year basis. During the same period in the previous year, the firm posted $10.96 earnings per share. On average, sell-side analysts predict that Regeneron Pharmaceuticals will post 38.58 EPS for the current fiscal year.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, EVP Marion Mccourt sold 1,000 shares of the company’s stock in a transaction on Monday, February 5th. The shares were sold at an average price of $934.71, for a total transaction of $934,710.00. Following the completion of the sale, the executive vice president now owns 13,789 shares in the company, valued at approximately $12,888,716.19. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Regeneron Pharmaceuticals news, EVP Marion Mccourt sold 1,000 shares of the company’s stock in a transaction on Monday, February 5th. The shares were sold at an average price of $934.71, for a total transaction of $934,710.00. Following the completion of the sale, the executive vice president now owns 13,789 shares in the company, valued at approximately $12,888,716.19. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Joseph L. Goldstein sold 2,707 shares of the company’s stock in a transaction on Tuesday, January 23rd. The shares were sold at an average price of $950.00, for a total transaction of $2,571,650.00. Following the completion of the sale, the director now owns 6,382 shares of the company’s stock, valued at approximately $6,062,900. The disclosure for this sale can be found here. In the last quarter, insiders have sold 13,729 shares of company stock valued at $13,124,641. 8.83% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Markel Corp boosted its stake in shares of Regeneron Pharmaceuticals by 1.3% during the 1st quarter. Markel Corp now owns 80,300 shares of the biopharmaceutical company’s stock worth $56,083,000 after buying an additional 1,000 shares during the last quarter. Cibc World Market Inc. boosted its stake in shares of Regeneron Pharmaceuticals by 1.4% during the 1st quarter. Cibc World Market Inc. now owns 6,416 shares of the biopharmaceutical company’s stock worth $4,481,000 after buying an additional 86 shares during the last quarter. Blair William & Co. IL boosted its stake in shares of Regeneron Pharmaceuticals by 18.4% during the 1st quarter. Blair William & Co. IL now owns 1,431 shares of the biopharmaceutical company’s stock worth $999,000 after buying an additional 222 shares during the last quarter. Sequoia Financial Advisors LLC boosted its stake in shares of Regeneron Pharmaceuticals by 23.1% during the 1st quarter. Sequoia Financial Advisors LLC now owns 495 shares of the biopharmaceutical company’s stock worth $346,000 after buying an additional 93 shares during the last quarter. Finally, Baird Financial Group Inc. boosted its stake in shares of Regeneron Pharmaceuticals by 100.9% during the 1st quarter. Baird Financial Group Inc. now owns 36,529 shares of the biopharmaceutical company’s stock worth $25,513,000 after buying an additional 18,345 shares during the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.